HIV-1 acute infection env glycomutants designed from 3D model: Effects on processing, antigenicity, and neutralization sensitivity

Virology

Volumn 324, Issue 1, 2004, Pages 90-102

  Reynard, Frédéric ^a   Fatmi, Ahmed ^a   Verrier, Bernard ^a   Bedin, Frédéric ^a  

^a BIOMÉRIEUX   (France)

Author keywords

Acute infection; Env glycoprotein; Env processing; HIV 1; N glycans; Neutralization

Indexed keywords

ENVELOPE PROTEIN; GLYCAN; SUGAR; VIRUS ENVELOPE PROTEIN;

ANTIGENICITY; ARTICLE; CLUSTER ANALYSIS; COMPARATIVE STUDY; DEGLYCOSYLATION; EMBRYO; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MUTANT; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; SERUM; VIRUS INFECTION; WILD TYPE;

AMINO ACID SEQUENCE; ANTIGENS, CD4; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MEMBRANE FUSION; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 2942525411     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2004.03.022     Document Type: Article

References (50)

1. Ataman-Onal Y., Coiffier C., Giraud A., Babic-Erceg A., Biron F., Verrier B. Comparison of complete env gene sequences from individuals with symptomatic primary HIV type 1 infection. AIDS Res. Hum. Retroviruses. 15(11):1999;1035-1039
2. Benjouad A., Gluckman J.C., Rochat H., Montagnier L., Bahraoui E. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J. Virol. 66(4):1992;2473-2483
3. Bolmstedt A., Sjolander S., Hansen J.E., Akerblom L., Hemming A., Hu S.L., Morein B., Olofsson S. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 12(3):1996;213-220
4. Brand D., Lemiale F., Thibault G., Verrier B., Lebigot S., Roingeard P., Buzelay L., Brunet S., Barin F. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity. Virology. 271(2):2000;350-362
5. Burrer R., Salmon-Ceron D., Richert S., Pancino G., Spiridon G., Haessig S., Roques V., Barre-Sinoussi F., Aubertin A.M., Moog C. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients. J. Virol. 75(11):2001;5421-5424
6. Burton D.R., Williamson R.A., Parren P.W. Antibody and virus: binding and neutralization. Virology. 270(1):2000;1-3
7. Cattaneo R., Rose J.K. Cell fusion by the envelope glycoproteins of persistent measles viruses which caused lethal human brain disease. J. Virol. 67(3):1993;1493-1502
8. Chackerian B., Rudensey L.M., Overbaugh J. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. J. Virol. 71(10):1997;7719-7727
9. Cheng-Mayer C., Brown A., Harouse J., Luciw P.A., Mayer A.J. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J. Virol. 73(7):1999;5294-5300
10. Delwart E., Magierowska M., Royz M., Foley B., Peddada L., Smith R., Heldebrant C., Conrad A., Busch M. Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS. 16(2):2002;189-195
11. Desrosiers R.C., Lifson J.D., Gibbs J.S., Czajak S.C., Howe A.Y., Arthur L.O., Johnson R.P. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72(2):1998;1431-1437
12. Dirckx L., Lindemann D., Ette R., Manzoni C., Moritz D., Mous J. Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity. Virus Res. 18(1):1990;9-20
13. Dubay J.W., Dubay S.R., Shin H.J., Hunter E. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J. Virol. 69(8):1995;4675-4682
14. Fennie C., Lasky L.A. Model for intracellular folding of the human immunodeficiency virus type 1 gp120. J. Virol. 63(2):1989;639-646
15. Fenouillet E., Gluckman J.C., Jones I.M. Functions of HIV envelope glycans. Trends Biochem. Sci. 19(2):1994;65-70
16. Fischer P.B., Karlsson G.B., Dwek R.A., Platt F.M. N- butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure. J. Virol. 70(10):1996;7153-7160
17. Freel S.A., Fiscus S.A., Pilcher C.D., Menezes P., Giner J., Patrick E., Lennox J.L., Hicks C.B.J.J. Jr., Shugars D.C. Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection. AIDS. 17(14):2003;2025-2033
18. Hemming A., Gram G.J., Bolmstedt A., Losman B., Hansen J.E., Ricksten A., Olofsson S. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies. Arch. Virol. 141(11):1996;2139-2151
19. Hu Q.X., Barry A.P., Wang Z.X., Connolly S.M., Peiper S.C., Greenberg M.L. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74(24):2000;11858-11872
20. Johnson W.E., Sauvron J.M., Desrosiers R.C. Conserved, N-linked carbohydrates of human immunodeficiency virus type 1 gp41 are largely dispensable for viral replication. J. Virol. 75(23):2001;11426-11436
21. Kolchinsky P., Kiprilov E., Bartley P., Rubinstein R., Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 75(7):2001;3435-3443
22. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393(6686):1998;648-659
23. Lee W.R., Syu W.J., Du B., Matsuda M., Tan S., Wolf A., Essex M., Lee T.H. Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 89(6):1992;2213-2217
24. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265(18):1990;10373-10382
25. Li Y.Y., Perez L.G. The entire SU subunit is required for the incorporation of the HIV-1 envelope glycoprotein complex into virions. Virus Genes. 14(3):1997;211-223
26. Li Y., Luo L., Rasool N., Kang C.Y. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J. Virol. 67(1):1993;584-588
27. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6(2):2000;207-210
28. Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K., Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62(6):1988;2107-2114
29. McCune J.M., Rabin L.B., Feinberg M.B., Lieberman M., Kosek J.C., Reyes G.R., Weissman I.L. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell. 53(1):1988;55-67
30. McKeating J.A., McKnight A., Moore J.P. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J. Virol. 65(2):1991;852-860
31. Moore J.P., Cao Y., Qing L., Sattentau Q.J., Pyati J., Koduri R., Robinson J., Barbas C.F. III, Burton D.R., Ho D.D. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69(1):1995;101-109
32. Moulard M., Decroly E. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. Biochim. Biophys. Acta. 1469(3):2000;121-132
33. Moulard M., Hallenberger S., Garten W., Klenk H.D. Processing and routage of HIV glycoproteins by furin to the cell surface. Virus Res. 60(1):1999;55-65
34. Nakayama E.E., Shioda T., Tatsumi M., Xin X., Yu D., Ohgimoto S., Kato A., Sakai Y., Ohnishi Y., Nagai Y. Importance of the N-glycan in the V3 loop of HIV-1 envelope protein for CXCR-4- but not CCR-5-dependent fusion. FEBS Lett. 426(3):1998;367-372
35. Ogert R.A., Lee M.K., Ross W., Buckler-White A., Martin M.A., Cho M.W. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dual tropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 75(13):2001;5998-6006
36. Ohgimoto S., Shioda T., Mori K., Nakayama E.E., Hu H., Nagai Y. Location-specific, unequal contribution of the N glycans in simian immunodeficiency virus gp120 to viral infectivity and removal of multiple glycans without disturbing infectivity. J. Virol. 72(10):1998;8365-8370
37. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77(1):2003;642-658
38. Park E.J., Vujcic L.K., Anand R., Theodore T.S., Quinnan G.V. Jr. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J. Virol. 72(9):1998;7099-7107
39. Pollakis G., Kang S., Kliphuis A., Chalaby M.I., Goudsmit J., Paxton W.A. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276(16):2001;13433-13441
40. Quinones-Kochs M.I., Buonocore L., Rose J.K. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 76(9):2002;4199-4211
41. Reitter J.N., Desrosiers R.C. Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J. Virol. 72(7):1998;5399-5407
42. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280(5371):1998;1949-1953
43. Sanders R.W., Vesanen M., Schuelke N., Master A., Schiffner L., Kalyanaraman R., Paluch M., Berkhout B., Maddon P.J., Olson W.C., Lu M., Moore J.P. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76(17):2002;8875-8889
44. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1→2 mannose residues on the outer face of gp120. J. Virol. 76(14):2002;7306-7321
45. Schonning K., Joost M., Gram G.J., Machuca R., Nielsen C., Nielsen J.O., Hansen J.E. Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 18(3):1998;195-202
46. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70(2):1996;1100-1108
47. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature. 422(6929):2003;307-312
48. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Michael Kilby J., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Corrigendum: antibody neutralization and escape by HIV-1. Nature. 423(6936):2003;197
49. Willey R.L., Martin M.A. Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120. J. Virol. 67(6):1993;3639-3643
50. Zhu X., Borchers C., Bienstock R.J., Tomer K.B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry. 39(37):2000;11194-11204